KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Restructuring Costs: 2009-2018

Historic Restructuring Costs for Vertex Pharmaceuticals (VRTX) over the last 10 years, with Dec 2018 value amounting to -$4,000.

  • Vertex Pharmaceuticals' Restructuring Costs fell 101.03% to -$4,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $184,000, marking a year-over-year decrease of 98.71%. This contributed to the annual value of -$184,000 for FY2018, which is 101.29% down from last year.
  • According to the latest figures from Q4 2018, Vertex Pharmaceuticals' Restructuring Costs is -$4,000, which was down 102.30% from $174,000 recorded in Q3 2018.
  • Vertex Pharmaceuticals' 5-year Restructuring Costs high stood at $40.8 million for Q3 2014, and its period low was -$3.3 million during Q1 2015.
  • Its 3-year average for Restructuring Costs is $1.3 million, with a median of $280,500 in 2016.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Restructuring Costs skyrocketed by 15,766.67% in 2014, and later plummeted by 152.88% in 2015.
  • Over the past 5 years, Vertex Pharmaceuticals' Restructuring Costs (Quarterly) stood at $4.2 million in 2014, then slumped by 63.40% to $1.5 million in 2015, then crashed by 85.30% to $224,000 in 2016, then surged by 72.77% to $387,000 in 2017, then slumped by 101.03% to -$4,000 in 2018.
  • Its last three reported values are -$4,000 in Q4 2018, $174,000 for Q3 2018, and -$62,000 during Q2 2018.